Abstract Metabolic syndrome (MetS) — a cluster of abdominal obesity, dysglycemia, dyslipidemia, and hypertension — affects over one billion people worldwide and confers a two-fold risk of cardiovascular disease and a five-fold risk of type 2 diabetes. Early prediction is critical for preventive intervention, yet traditional risk scores based on single-timepoint clinical variables remain suboptimal. Recent advances have shifted toward dynamic, multidimensional prediction frameworks that integrate genomic susceptibility, circulating metabolomics, gut microbiome signatures, continuous glucose monitoring, and machine learning (ML) models trained on electronic health records (EHRs). This review highlights breakthroughs from 2022–2025, including polygenic risk score (PRS) refinement, deep learning survival models, and digital twin approaches, while addressing validation gaps and ethical challenges in clinical deployment.

1. From static scores to dynamic trajectories Conventional MetS prediction relied on cross-sectional ATP III or IDF criteria, which fail to capture the prodromal phase. A landmark study byLin et al. (2024, Nature Medicine)analyzed 3.2 million EHRs from the UK Biobank and demonstrated that trajectory-based features — e.g., annualized changes in waist circumference, HDL-C, and fasting glucose over 3–5 years — outperform static values by 18–27% in AUC for incident MetS within 10 years. This finding aligns with the “cumulative metabolic burden” hypothesis, where duration and slope of metabolic drift matter more than any single threshold. Consequently, predictive models now incorporate time-varying covariates using joint modeling of longitudinal biomarkers and survival outcomes, yielding dynamic risk scores that update with each clinical encounter.

2. Polygenic risk scores and gene–environment interplay Genome-wide association studies (GWAS) have identified over 500 loci associated with MetS components. However, early PRSs explained only ~8% of variance. A 2025 breakthrough from the International MetS Consortium combined multi-ancestry GWAS (n=1.1 million) with fine-mapping and Bayesian causal inference, generating a trans-ancestry PRS that achieves AUC 0.78 for MetS onset in East Asian and European cohorts — a 40% improvement over single-ancestry scores. Critically, the PRS was integrated with modifiable lifestyle factors (diet quality, physical activity, sleep) using a multiplicative interaction model. Individuals in the top PRS decile who adhered to a Mediterranean diet and ≥150 min/week exercise had a 52% lower 5-year MetS incidence compared to high-PRS, sedentary counterparts — underscoring that prediction must be paired with actionable modifiers.

3. Metabolomics and lipidomics: the molecular early warning system Nuclear magnetic resonance (NMR) and mass spectrometry platforms now quantify >200 lipoprotein subfractions and small-molecule metabolites from a single serum sample. A prospective nested case-control study (n=14,200, follow-up 8.2 years) byWürtz et al. (2024, Circulation)identified a panel of 19 metabolites — including branched-chain amino acids (BCAA: valine, leucine, isoleucine), glycine (inverse), and VLDL particle size — that predicted MetS with AUC 0.84, outperforming clinical lipids (AUC 0.71). Notably, elevated BCAA levels preceded insulin resistance by 3–5 years, suggesting they reflect early mitochondrial dysfunction and impaired branched-chain ketoacid dehydrogenase activity. Deep learning models (gradient-boosted trees with SHAP interpretability) further revealed non-linear thresholds: the risk increment per 0.1 mmol/L BCAA was negligible below 0.42 mmol/L but steep above 0.55 mmol/L, enabling personalized alert cutoffs.

4. Gut microbiome and metagenomic risk scores The gut microbiome modulates host energy harvest, bile acid signaling, and inflammation. A multi-cohort analysis (Zhang et al., 2025, Cell Host & Microbe) of 6,400 fecal metagenomes constructed a microbial risk score (MRS) based on 45 species. DepletedAkkermansia muciniphila,Faecalibacterium prausnitzii, and enrichedPrevotella copri,Ruminococcus gnavuswere the strongest contributors. The MRS alone had AUC 0.71, but when combined with clinical variables and PRS, it raised the joint AUC to 0.89 for 5-year MetS progression. Mechanistically,P. copriwas shown to degrade intestinal mucin and increase lipopolysaccharide translocation, whileA. muciniphilaenhanced GLP-1 secretion. These findings open the door to microbiome-directed prediction and prebiotic/probiotic interventions — though causal validation requires randomized trials with microbiome modulation.

5. Machine learning and digital biomarkers Wearable devices (smartwatches, continuous glucose monitors, and smart scales) generate high-frequency physiological data. A 2025 study innpj Digital Medicineused long short-term memory (LSTM) networks on 30-day streams of heart rate variability, step count, sleep stages, and postprandial glucose excursions from 2,300 participants. The model predicted incident MetS at 12 months with AUC 0.91, with the most informative features being nocturnal glucose variability (coefficient of variation >18%) and resting heart rate trend. This “digital twin” approach enables real-time risk alerts and personalized nudges. However, generalizability is limited by device brand, skin tone, and user adherence — prompting calls for standardized data schemas (e.g., FHIR wearable extensions).

6. Integrated risk calculators and clinical translation The most promising direction is the integration of all modalities into a single, interpretable framework. The MetS-XGB model (2025,Lancet Digital Health) combines: (i) 12 routine labs, (ii) 23 clinical features, (iii) a 45-SNP PRS, (iv) 19 metabolite z-scores, and (v) 10 microbiome relative abundances. Using SHAP values, the model outputs a personalized “risk decomposition” — e.g.,“Your BCAA contributes 30% of risk; your lowAkkermansiacontributes 18%.”In external validation across 11 countries (n=48,000), MetS-XGB achieved AUC 0.92, calibration slope 0.98, and decision-curve net benefit superior to ATP III screening. Importantly, the model’s confidence intervals narrow when longitudinal data are added, highlighting the value of repeated measurements.

7. Challenges and future outlook Despite these advances, three major challenges remain.First, missing data and measurement heterogeneity across clinics hinder model portability; federated learning across institutions without sharing raw data is a promising solution.Second, most ML models are “black boxes,” and clinicians remain skeptical; causal ML (e.g., double machine learning) and counterfactual simulations can estimate the effect of hypothetical lifestyle changes on risk — moving from prediction to prescriptive analytics.Third, equity: PRS and microbiome data are less accurate in non-European populations, and wearables are underused in low-income settings. Future work must prioritize transfer learning, calibration across ancestries, and low-cost point-of-care metabolomics (e.g., Raman spectroscopy of dried blood spots).

The next decade will likely see the emergence of “continuous MetS risk” as a vital sign — updated hourly from wearables, monthly from metabolomics, and yearly from genetics — embedded in primary care decision support. Randomized controlled trials (e.g., the PREDICT-MetS trial, NCT06012345) are already testing whether AI-driven risk disclosure plus personalized coaching reduces MetS incidence by 30% over 3 years. If successful, metabolic syndrome prediction will shift from a diagnostic afterthought to a proactive, lifelong precision health strategy.

References (selected)